Shanghai Pharmaceuticals Holding Co Ltd (601607) — Capital Reinvestment Ratio
Shanghai Pharmaceuticals Holding Co Ltd (601607) has a Capital Reinvestment Ratio of 0.31x as of September 2025, meaning it reinvests 0% of its operating cash flow (CN¥1.56 Billion) in capital expenditures (CN¥487.63 Million). See 601607 equity financing ratio to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Shanghai Pharmaceuticals Holding Co Ltd Capital Reinvestment Ratio (1999–2025)
This chart tracks Shanghai Pharmaceuticals Holding Co Ltd's Capital Reinvestment Ratio across 27 annual periods. Check Shanghai Pharmaceuticals Holding Co Ltd (601607) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Shanghai Pharmaceuticals Holding Co Ltd (1999–2025)
Year-by-year Capital Reinvestment Ratio for Shanghai Pharmaceuticals Holding Co Ltd from 1999 to 2025. For live market cap and broader valuation context, see Shanghai Pharmaceuticals Holding Co Ltd market cap and net worth.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.38x | CN¥6.15 Billion | CN¥2.33 Billion | ▼ -8.3% |
| 2024 | 0.41x | CN¥5.83 Billion | CN¥2.40 Billion | ▼ -27.4% |
| 2023 | 0.57x | CN¥5.23 Billion | CN¥2.97 Billion | ▲ +0.3% |
| 2022 | 0.57x | CN¥4.74 Billion | CN¥2.68 Billion | ▼ -30.4% |
| 2021 | 0.81x | CN¥5.06 Billion | CN¥4.12 Billion | ▲ +85.1% |
| 2020 | 0.44x | CN¥6.84 Billion | CN¥3.01 Billion | ▼ -3.8% |
| 2019 | 0.46x | CN¥6.02 Billion | CN¥2.75 Billion | ▼ -26.2% |
| 2018 | 0.62x | CN¥3.14 Billion | CN¥1.94 Billion | ▼ -18.2% |
| 2017 | 0.76x | CN¥2.65 Billion | CN¥2.01 Billion | ▼ -30.4% |
| 2016 | 1.09x | CN¥1.95 Billion | CN¥2.12 Billion | ▼ -14.6% |
| 2015 | 1.28x | CN¥1.35 Billion | CN¥1.72 Billion | ▲ +31.9% |
| 2014 | 0.97x | CN¥1.34 Billion | CN¥1.29 Billion | ▲ +4.0% |
| 2013 | 0.93x | CN¥973.45 Million | CN¥905.06 Million | ▲ +50.9% |
| 2012 | 0.62x | CN¥1.15 Billion | CN¥708.91 Million | ▲ +164.0% |
| 2011 | 0.23x | CN¥1.77 Billion | CN¥413.54 Million | ▼ -28.5% |
| 2010 | 0.33x | CN¥1.69 Billion | CN¥550.30 Million | ▲ +171.1% |
| 2009 | 0.12x | CN¥664.13 Million | CN¥79.97 Million | ▼ -62.0% |
| 2008 | 0.32x | CN¥285.68 Million | CN¥90.50 Million | ▼ -19.4% |
| 2007 | 0.39x | CN¥488.94 Million | CN¥192.29 Million | ▲ +51.3% |
| 2006 | 0.26x | CN¥583.11 Million | CN¥151.60 Million | ▼ -90.4% |
| 2005 | 2.71x | CN¥73.00 Million | CN¥198.09 Million | ▼ -34.2% |
| 2004 | 4.13x | CN¥61.66 Million | CN¥254.38 Million | ▼ -98.8% |
| 2003 | 350.18x | CN¥484.27K | CN¥169.58 Million | ▲ +12537.3% |
| 2002 | 2.77x | CN¥100.84 Million | CN¥279.44 Million | ▲ +25.9% |
| 2001 | 2.20x | CN¥65.73 Million | CN¥144.71 Million | ▲ +128.2% |
| 2000 | 0.96x | CN¥146.22 Million | CN¥141.09 Million | ▲ +202.8% |
| 1999 | 0.32x | CN¥164.67 Million | CN¥52.48 Million | — |